AR128130A2 - Métodos para evaluar conveniencia de un filtro bioquímico - Google Patents

Métodos para evaluar conveniencia de un filtro bioquímico

Info

Publication number
AR128130A2
AR128130A2 ARP220103612A ARP220103612A AR128130A2 AR 128130 A2 AR128130 A2 AR 128130A2 AR P220103612 A ARP220103612 A AR P220103612A AR P220103612 A ARP220103612 A AR P220103612A AR 128130 A2 AR128130 A2 AR 128130A2
Authority
AR
Argentina
Prior art keywords
methods
filters
biochemical filter
evaluate suitability
endotoxins
Prior art date
Application number
ARP220103612A
Other languages
English (en)
Inventor
Nathan Mao
Annamarie Cruz
Bernhard Schilling
Scott Carver
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR128130A2 publication Critical patent/AR128130A2/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D24/00—Filters comprising loose filtering material, i.e. filtering material without any binder between the individual particles or fibres thereof
    • B01D24/02—Filters comprising loose filtering material, i.e. filtering material without any binder between the individual particles or fibres thereof with the filter bed stationary during the filtration
    • B01D24/10—Filters comprising loose filtering material, i.e. filtering material without any binder between the individual particles or fibres thereof with the filter bed stationary during the filtration the filtering material being held in a closed container
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M37/00—Means for sterilizing, maintaining sterile conditions or avoiding chemical or biological contamination
    • C12M37/02—Filters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/579—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving limulus lysate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Sustainable Development (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

Realizaciones de la presente revelación incluyen métodos y sistemas para detectar la presencia de endotoxinas en filtros. Por ejemplo, realizaciones de la presente revelación se dirigen a métodos y sistemas para mejorar controles en procesos mediante detección de cantidades no deseadas de endotoxinas en filtros que contienen materiales que provienen de fuentes que se dan naturalmente previo a usar aquellos filtros en la producción de sustancias farmacéuticas formuladas.
ARP220103612A 2018-05-02 2022-12-27 Métodos para evaluar conveniencia de un filtro bioquímico AR128130A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862665721P 2018-05-02 2018-05-02

Publications (1)

Publication Number Publication Date
AR128130A2 true AR128130A2 (es) 2024-03-27

Family

ID=67106126

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP190101127A AR114848A1 (es) 2018-05-02 2019-04-29 Métodos para evaluar conveniencia de un filtro bioquímico
ARP220103612A AR128130A2 (es) 2018-05-02 2022-12-27 Métodos para evaluar conveniencia de un filtro bioquímico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP190101127A AR114848A1 (es) 2018-05-02 2019-04-29 Métodos para evaluar conveniencia de un filtro bioquímico

Country Status (7)

Country Link
US (2) US11378571B2 (es)
EP (1) EP3787766A1 (es)
CN (2) CN116212464A (es)
AR (2) AR114848A1 (es)
CA (1) CA3097903A1 (es)
TW (2) TW202348297A (es)
WO (1) WO2019212881A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114602237B (zh) * 2022-03-10 2023-11-28 华兰生物工程股份有限公司 一种从人血浆或人血浆衍生原料中去除内毒素的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM388494A0 (en) 1994-02-16 1994-03-10 Csl Limited Process for removing endotoxins
DE69623196T3 (de) * 1995-06-30 2019-11-21 Toray Industries, Inc. Permselektive Membranen und Verfahren zu ihrer Herstellung
US6953686B1 (en) * 1999-05-28 2005-10-11 Cambrex Bio Science Baltimore, Inc. Methods of DNA purification and purified DNA
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7083987B2 (en) * 2001-02-05 2006-08-01 Activx Biosciences, Inc. Activity based probe analysis
US6942802B2 (en) * 2001-04-13 2005-09-13 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
WO2003002731A1 (en) * 2001-06-29 2003-01-09 Hemebiotech A/S A PROCESS FOR PURIFICATION OF RECOMBINANT PORPHOBILINOGEN DEAMINASE (rhPBGD)
FR2840992B1 (fr) * 2002-06-18 2004-09-03 Hemosystem Procede de denombrement et/ou d'identification morphologique de leucocytes en phase solide
CA2621047A1 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US20110159130A1 (en) * 2007-02-28 2011-06-30 Sanjay Jain Reduction of endotoxin in polysialic acids
WO2008148010A1 (en) * 2007-05-23 2008-12-04 Vgx Pharmaceuticals, Inc. Composition comprising high concentration of biologically active molecules and processes for preparing the same
DE102008037678A1 (de) * 2008-08-14 2010-02-25 Sartorius Stedim Biotech Gmbh Tiefenfilterschicht mit anorganischem Schichtdoppelhydroxid
LT2848625T (lt) * 2008-08-14 2019-10-10 Genentech, Inc. Priemaišų pašalinimo būdai, panaudojant reziduojančio baltymo pakeitimą jonų mainų membraninės chromatografijos pagalba
US8277649B2 (en) 2009-12-14 2012-10-02 General Electric Company Membranes and associated methods for purification of antibodies
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
US8941405B2 (en) 2012-08-03 2015-01-27 International Business Machines Corporation FET pair based physically unclonable function (PUF) circuit with a constant common mode voltage
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20160013173A (ko) 2013-08-30 2016-02-03 이엠디 밀리포어 코포레이션 추출가능물이 적은 대용량 복합 심층 필터 매질
JP2017536391A (ja) 2014-12-02 2017-12-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−６ｒアンタゴニストを投与することによってドライアイ疾患を治療するための方法
CN105251049B (zh) 2015-09-29 2018-04-10 浙江星月生物科技股份有限公司 一种去除生物医用材料中细菌内毒素的离子缓冲液及应用

Also Published As

Publication number Publication date
TW202348297A (zh) 2023-12-16
EP3787766A1 (en) 2021-03-10
US20190339254A1 (en) 2019-11-07
CN112020384A (zh) 2020-12-01
CN112020384B (zh) 2023-03-10
TW201946687A (zh) 2019-12-16
US20220404335A1 (en) 2022-12-22
AR114848A1 (es) 2020-10-21
TWI814812B (zh) 2023-09-11
CN116212464A (zh) 2023-06-06
CA3097903A1 (en) 2019-11-07
WO2019212881A1 (en) 2019-11-07
US11378571B2 (en) 2022-07-05

Similar Documents

Publication Publication Date Title
EA201691364A1 (ru) Способ превращения смеси пластмассовых отходов (mwp) в ценные нефтехимические продукты
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
BR112017001212A2 (pt) processamento de biomassa
CL2019001517A1 (es) Anticuerpos y métodos de su utilización.
CO2018000244A2 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
AR128130A2 (es) Métodos para evaluar conveniencia de un filtro bioquímico
CU20150104A7 (es) Método de separación de sólidos de líquidos de un lodo que comprende biomasa
MX2017007766A (es) Material no tejido, metodo para fabricar el mismo y articulos que incorporan el material no tejido.
BR112017026558B8 (pt) Cartucho para a separação de uma mistura de fluidos, módulo de separação de fluidos e método para a separação de uma mistura composta por pelo menos dois fluidos
EA201692157A1 (ru) Синтез двухцепочечных нуклеиновых кислот
MX2021009746A (es) Materiales polimericos de ciclodextrina con carga y metodos para su fabricacion y uso.
AR119393A1 (es) Anticuerpos que se unen a nkg2d
BR112018067951A2 (pt) moléculas que se ligam a ilt7 e métodos de uso destas
UY37683A (es) Anticuerpo monoclonal anti-pd-l1 monoclonal
AR104358A1 (es) Método para la purificación de proteínas
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
PL439807A1 (pl) Sposoby oczyszczania przeciwciał i ich kompozycje
TR201901872T4 (tr) Kağıt hamuru ve kağıt endüstrisinin yan akışlarını ve atık akışlarını işleme yöntemi ve bir gübre.
CO2018010286A2 (es) Método para la purificación de proteínas
ZA202203400B (en) Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysis
CL2021001104A1 (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
EP4310184A3 (en) Methods of screening antigen-binding molecules by normalizing for the concentration of antigen-binding molecule
BR112021021673A2 (pt) Método para melhorar o emparelhamento preferencial de uma cadeia pesada e uma cadeia leve de um anticorpo e anticorpo
BR112021012302A8 (pt) Métodos e produtos para converter dióxido de carbono em um ou mais compostos orgânicos pequenos
MX2023007357A (es) Ensayo de gradiente de difusion para moleculas que contienen anti-cd3.